(Q46941434)

26 December 2017

title

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone (English)

1 reference

26 December 2017

0 references

1 reference

Joi L Dunbar

1

1 reference

26 December 2017

Ryan Z Turncliff

2

1 reference

26 December 2017

Qunming Dong

3

1 reference

26 December 2017

Bernard L Silverman

4

1 reference

26 December 2017

Elliot W Ehrich

5

1 reference

26 December 2017

Kenneth C Lasseter

6

1 reference

26 December 2017

publication date

1 March 2006

1 reference

26 December 2017

Alcoholism: Clinical and Experimental Research

published in

1 reference

26 December 2017

volume

30

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

480-490

1 reference

26 December 2017

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Rate-corrected QT interval: techniques and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Development of medications for alcohol use disorders: recent advances and ongoing challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Adverse effects of oral naltrexone: analysis of data from two clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2006.00052.X

10.1111/J.1530-0277.2006.00052.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017